262 related articles for article (PubMed ID: 22189054)
1. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
Dienstmann R; De Dosso S; Felip E; Tabernero J
Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
[TBL] [Abstract][Full Text] [Related]
2. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
5. [Research Progress of New Generation EGFR-TKIs after Third-generation].
Liu Y; Li Y; Wang J
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):970-975. PubMed ID: 32773008
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
Ni L; Nie L
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
[TBL] [Abstract][Full Text] [Related]
7. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
8. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC; Lin CC; Lee JH; Yang JC
J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
[TBL] [Abstract][Full Text] [Related]
9. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
10. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
11. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
Shah RR; Shah DR
Drug Saf; 2019 Feb; 42(2):181-198. PubMed ID: 30649743
[TBL] [Abstract][Full Text] [Related]
13. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Mukherji D; Spicer J
Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
16. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
Zhang H; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.
Zhang YC; Zhou Q; Wu YL
Cancer Lett; 2019 Sep; 459():240-247. PubMed ID: 31201840
[TBL] [Abstract][Full Text] [Related]
18. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
19. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ricordel C; Friboulet L; Facchinetti F; Soria JC
Ann Oncol; 2018 Jan; 29(suppl_1):i28-i37. PubMed ID: 29462256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
